Literature analysis of Oxaliplatin Allergic Reactions in Chinese patients

doi:10.19803/j.1672-8629.2020.11.11

Abstract

Abstract: Objective To collect case reports on oxaliplatin (OXA)-induced allergic reactions in Chinese patients, summarize their characteristics and regularities, and improve the safety of OXA in clinical application. Methods Chinese literature databases including Wanfang and CNKI etc from January 1999 fo May 2019. were searched for case reports of OXA-induced allergic reactions. Data on gender, age, chemotherapy cycles, the time allergic reactions occurred, dosage, clinical manifestations, severity and outcomes of the patients was statistically analyzed. Results A total of 102 OXA allergic reactions were reported. The average age of patients was 53 years old and the male-female ratio was 1.04:1. OXA-induced allergic reactions can occur in any cycle of medication, mostly within 30min, which can involve multiple systems such as digestive, cardiovascular and respiratory systems. Most of these allergic reactions are grade III, and all of these cases have improved after drug withdrawal or treatment. Conclusion Allergic reactions are common with OXA, which can lead to the interruption of chemotherapy. Severe allergy even poses a threat to patients' safety. The clinical medical staff should be alert to the allergic reactions of OXA, strengthen monitoring and prevention, and improve the safety of medication for patients.

Key words: oxaliplatin, ADR, allergic reactions, drug safety

CLC Number:

R994.11

LI Min, ZHONG Qiaoni, ZHAO Li, LAN Lulu, LIU Dong, ZHANG Chengliang. Literature analysis of Oxaliplatin Allergic Reactions in Chinese patients[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 798-802.

References

[1] Wang H, Xu L, Zhao L, et al.Literature Analysis of 126 Cases of Adverse Drug Reactions Induced by Oxaliplatin[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(2): 110-114.
[2] Georg Lenz, Ulrich T. Hacker,Wolfgang Kern., et al.Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution[J].Anti-cancer Drug, 2003, 14(9):731-733.
[3] MaindraultGoebel F, André T, Tournigand C,et al.Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients[J]. Eur J Cancer, 2005, 41(15): 2262-2267.
[4] Ichikawa Y, Goto A, Hirokawa S,et al.Allergic Reactions to Oxaliplatin in a Single Institute in Japan[J].Jpn J Clin Oncol, 2009, 39(9): 616-620.
[5] Song QY,Li T.Oxaliplatin induced anaphylaxis in 1 patient[J]. China Practical Medicine(中国实用医药), 2014, 9(3):195-196.
[6] Li HH.Anaphylaxis induced by oxaliplatin for injection in 1 case[J]. China Medical Herald(中国医药导报), 2011, 8(13): 130.
[7] Basketter D A, McFadden J P, Kimber I.Assessing the severity of allergic reactions: a regulatory dilemma[J].Contact Dermatitis, 2012, 67(1): 3-8.
[8] Mori Y, Nishimura T, Kitano T,et al.Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX[J].Oncology, 2010, 79(1-2): 136-143.
[9] Siu SWK, Chan RTT, Au GKH.Hypersensitivity reactions to oxaliplatin: experience in a single institute[J]. Official Journal of the European Society for Medical Oncology, 2006, 17(2): 259-261.
[10] Micheli L, Mattoli L, Maidecchi A,et al.Effect of Vitis vinifera hydroalcoholic extract against oxaliplatin neurotoxicity: in vitro and in vivo evidence[J].Sci Rep, 2018, 8(1): 14364.
[11] Lee K, Park Y J, Kim E S,et al.Hypersensitivity Reactions to Oxaliplatin[J].Cancer Res Treat, 2006, 38(4): 240-241.
[12] Kim BH, Bradley T, Tai J,et al.Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review[J].Oncology, 2009, 76(4): 231-238.
[13] Zeng PH, Shu LL, Xie XH, et al.Comparative analysis of clinical and endoscopic data of colorectal cancer patients of different ages[J].The New Med, 2005(8): 451-453.
[14] Zhao B, Zhong HG,Gao F, et al.Epidemiological analysis of 3720 cases of colorectal cancer in Guangxi[J].Guangdong Medical, 2013, 34(14): 2239-2242.
[15] Rogers BB, Cuddahy T, Briscella C,et al.Oxaliplatin: Detection and Management of Hypersensitivity Reactions[J].Clin J Oncol Nurs, 2019, 23(1): 68-75.
[16] Brandi G, Pantaleo M A, Galli C,et al.Hypersensitivity reactions related to oxaliplatin (OHP)[J].Brit J Cancer, 2003, 89(3): 477-481.
[17] Castells MCMP, Tennant NMB, Sloane DEM,et al.Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensi-tization in 413 cases[J].J of Allerg and Clin Immunol, 2008, 122(3): 574-580.
[18] Zhang X, Zhao Y, Dong Y.The Effects of Prolonged Infusion on Reducing Oxaliplatin Hypersensitivity Reactions[J].J Investig Allergol Clin Immunol, 2017, 27(1): 65-66.
[19] Li Xiaotong,Zhai Suodi,Wang Qiang,et al.First aid guide for severe allergic reactions[J].Adverse Drug Reactions Journal, 2019, 21(2): 85-91.
[20] Parel M, Ranchon F, Nosbaum A, et al.Hypersensitivity to oxaliplatin: clinical features and risk factors[J].Bmc Pharmacol Toxicol, 2014, 15: 1.
[21] Xu Y, Chen L, Zhu H, et al.Rationality and Safety of Oxaliplatin Prescription[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2016,13(3):176-179.
[22] Waddle M, Irvin M, Gupta E,et al.Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion[J].Chemother, 2017, 62(5): 295-300.
[23] Lai J, Wang W.Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review[J].Pharmacy World & Science, 2009, 31(5): 538-541.
[24] Garciaz S, Oziel-Taieb S, Dermeche S,et al.Acute immune hematological complication of oxaliplatin. A series of 3 cases[J]. Tumori, 2014, 100(1): 17-19.
[25] Yamauchi H, Goto T, Takayoshi K,et al.A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin[J].Eur J Cancer Care, 2015, 24(1): 111-116.
[26] Nishihara M, Nishikura K, Morikawa N,et al.Factors Influencing the Appearance of Oxaliplatin-Induced Allergy[J].Biol Pharm Bull, 2017, 40(12): 2105-2109.
[27] Bonadonna MPP.Skin Test Protocol for the Prevention of Hypers-ensitivity Reactions to Oxaliplatin[J].Anti-cancer Res, 2014, 34: 537-540.
[28] Nozawa HMP, Muto YMP, Yamada YMP.Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer[J].Clin Ther, 2008, 30(6): 1160-1165.
[29] Rose PG, Metz C, Link N.Desensitization With Oxaliplatin in Patients Intolerant of Carboplatin Desensitization[J].Intern J of Gynecol Cancer, 2014, 24(9): 1603-1606.
[30] Takako Y, Iwasa S, Hashimoto H.Successful Rechallenge for Oxaliplatin Hypersensitivity Reactions in Patients with Metastatic Colorectal Cancer[J].Anti-cancer Res, 2012, 32: 5521-5526.
[31] Lydia Mis,Nishan HF,Hurbert IH,et al.Successful Desens-itization to Oxaliplatin[J].The Annals of Pharmacotherapy, 2005, 39: 966-969.